Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xianggui Yuan
Observed names:
Xiang-Gui Yuan,
Xiang-gui Yuan,
Xiang‐Gui Yuan,
Xiang‑Gui Yuan
Institutions:
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
Observed institutions:
National Natural Science Foundation of China,
Second Affiliated Hospital of Zhejiang University,
European Society for Blood and Marrow Transplantation,
First Affiliated Hospital Zhejiang University,
Zhejiang University
ORCID:
0000-0003-0920-6171
Observed ORCID:
0000-0003-0920-6171
OpenAlex ID:
A5042550415
MicroRNAs expression signatures are associated with lineage and survival in acute leukemias
2010
·
Yungui Wang
, Zejuan Li
, et al.
·
Blood Cells Molecules and Diseases
·
153
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial
2025
·
Wen Lei
, Hui Liu
, et al.
·
Nature Cancer
·
88
Gorham-Stout syndrome in mainland China: a case series of 67 patients and review of the literature
2013
·
Po Hu
, Xiang-gui Yuan
, et al.
·
Journal of Zhejiang University SCIENCE B
·
77
PDF
Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases
2019
·
Xiang-Gui Yuan
, Yu-Rong Huang
, et al.
·
Annals of Hematology
·
34
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase‑dependent manner
2019
·
Xiang‑Gui Yuan
, Yu‑Rong Huang
, et al.
·
Oncology Letters
·
33
PDF
Renal complications of Castleman’s disease: report of two cases and analysis of 75 cases
2011
·
Xiang-Gui Yuan
, Wen Hu
, et al.
·
Clinical and Experimental Nephrology
·
25
Oestrogen‐deficiency inducing haematopoiesis dysfunction via reduction in haematopoietic stem cells and haematopoietic growth factors in rats
2012
·
Xi Qiu
, Xiang‐Gui Yuan
, et al.
·
International Journal of Experimental Pathology
·
19
Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
2022
·
Xianggui Yuan
, Xian Li
, et al.
·
Frontiers in Immunology
·
16
PDF
CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report
2022
·
Zhuanyi Sun
, Caiqin Xie
, et al.
·
Frontiers in Immunology
·
14
PDF
Safety and Efficacy of CD19 CAR-T Cells Co-Expressing IL-7 and CCL19 in Combination with Anti-PD-1 Antibody for Refractory/Relapsed DLBCL: Preliminary Data from the Phase Ⅰb Trial (NCT04381741)
2021
·
Wenbin Qian
, Aiqi Zhao
, et al.
·
Blood
·
10
High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease
2011
·
Xiang-Gui Yuan
, Fei-Fei Chen
, et al.
·
Annals of Hematology
·
10
Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review
2023
·
Xueli Jin
, Hui Liu
, et al.
·
Journal of Zhejiang University SCIENCE B
·
9
PDF
Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
2022
·
Yuan-Yuan Hao
, Pan-Pan Chen
, et al.
·
World Journal of Clinical Cases
·
9
Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy
2022
·
Weiguo Zhu
, Shi Tao
, et al.
·
Frontiers in Immunology
·
9
PDF
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
2024
·
Xianggui Yuan
, Yaping Xie
, et al.
·
Haematologica
·
8
PDF
miR-433 Inhibits Glioblastoma Progression by Suppressing the PI3K/Akt Signaling Pathway Through Direct Targeting of ERBB4
2023
·
Huawei Jiang
, Zhiwei Su
, et al.
·
OMICS A Journal of Integrative Biology
·
8
Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
2022
·
Xianggui Yuan
, Teng Yu
, et al.
·
Scientific Reports
·
7
PDF
Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing in Chinese patients
2023
·
Xianggui Yuan
, Teng Yu
, et al.
·
Frontiers of Medicine
·
6
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial
2025
·
Wen Lei
, Hui Liu
, et al.
·
Nature Cancer
·
5
PDF
Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome
2012
·
Xiao-Hua Xu
, Lian-Sheng Huang
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
4
Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma
2026
·
Xianggui Yuan
, Qian Luo
, et al.
·
American Journal of Hematology
·
3
Design, preclinical evaluation, and multicenter phase 1 clinical study of HZ-A-018 for relapsed or refractory central nervous system lymphoma
2026
·
Shenglan Li
, Jialiang Lu
, et al.
·
Acta Pharmaceutica Sinica B
·
2
Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study
2024
·
Wenbin Li
, Zhuang Kang
, et al.
·
Blood
·
2
Lenalidomide, Rituximab and Methotrexate(R2-MTX)in Newly Diagnosed Primary Central Nervous System Lymphoma
2021
·
Xianggui Yuan
, Yun Liang
, et al.
·
Blood
·
2
[Effect of gap junction on the cardioprotection of ischemic postconditioning in rat heart].
2009
·
Hong-Jiao Mao
, Bao-Ping Chen
, et al.
·
PubMed
·
2
Show more works
View as search
Works count:
35
Citation count:
559
H-index:
10
I10-index:
11
Year
Topic
Type